<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00954642</url>
  </required_header>
  <id_info>
    <org_study_id>ANP4667g</org_study_id>
    <nct_id>NCT00954642</nct_id>
  </id_info>
  <brief_title>A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase Ib, open-label, dose-escalation study of MNRP1685A given by intravenous (IV)
      infusion as therapy for locally advanced or metastatic solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of dose-limiting toxicities (DLTs)</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters of MNRP1685A and bevacizumab, when appropriate, as data allow (total exposure, maximum and minimum serum concentration, clearance, and volume of distribution)</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Solid Cancers</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MNRP1685A</intervention_name>
    <description>Escalating intravenous dose</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adequate hematologic and end organ function

          -  Evaluable disease or measurable disease per Response Evaluation Criteria In Solid
             Tumors (RECIST)

          -  Agreement to use an effective form of contraception for the duration of the study

        Inclusion Criteria Unique to Arm A:

          -  Histologically or cytologically documented, incurable, locally advanced, or metastatic
             solid malignancy that has progressed on, or failed to respond to, at least one prior
             regimen

        Inclusion Criteria Unique to Arm B:

          -  Histologically or cytologically documented, incurable, locally advanced, or metastatic
             solid malignancy; a maximum of two prior chemotherapy regimens is allowed

        Exclusion Criteria:

          -  Any anti-cancer therapy, including chemotherapy, hormonal therapy, or radiotherapy,
             within 3 weeks or 5 half-lives (for systemic agents), whichever is shorter, prior to
             initiation of study treatment with the following exceptions: hormonal therapy with
             gonadotropin-releasing hormone (GnRH) agonists or antagonists for prostate cancer;
             herbal therapy &gt; 1 week prior to Day 1; hormone-replacement therapy or oral
             contraceptives; palliative radiotherapy for bone metastases &gt; 2 weeks prior to Day 1

          -  Any condition requiring full-dose anticoagulants, such as warfarin, heparin, or
             thrombolytics, or a filter of the inferior vena cava

          -  Leptomeningeal disease as a manifestation of the current malignancy

          -  Active infection requiring IV antibiotics

          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory
             drugs, inhaled corticosteroids, or the equivalent of ≤ 10 mg/day prednisone

          -  Bisphosphonate therapy for symptomatic hypercalcemia

          -  Known clinically significant liver disease, including active viral, alcoholic, or
             other hepatitis, or cirrhosis

          -  Known human immunodeficiency virus (HIV) infection

          -  Known primary CNS malignancy, or untreated or active CNS metastases

          -  Pregnancy, lactation or breast feeding

          -  Inadequately controlled hypertension

          -  History of hypertensive crisis or hypertensive encephalopathy

          -  History of myocardial infarction or unstable angina within 6 months prior to Day 1

          -  New York Heart Association (NYHA) Class II or greater CHF

          -  History of stroke or transient ischemic attack (TIA) within 6 months prior to Day 1

          -  Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or
             recent peripheral arterial thrombosis) within 6 months prior to Day 1

          -  History of hemoptysis within 1 month prior to Day 1

          -  Evidence of bleeding diathesis or significant coagulopathy in the absence of stable
             therapeutic anticoagulation

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 1 or anticipation of need for major surgical procedure during the course
             of the study

          -  Core biopsy or other minor surgical procedure, excluding placement of a vascular
             access device, within 7 days prior to Day 1

          -  History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
             within 6 months prior to Day 1

          -  Clinical signs or symptoms of gastrointestinal obstruction or requirement for
             parenteral hydration, parenteral nutrition, or tube feeding because of an active
             gastrointestinal condition

          -  Evidence of abdominal free air not explained by paracentesis or recent surgical
             procedure

          -  Serious, non-healing wound, active gastrointestinal ulcer, or untreated bone fracture

          -  Intrathoracic lung carcinoma of squamous cell histology

          -  Grade ≥ 2 sensory neuropathy

          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding that, in the investigator's opinion, gives reasonable suspicion of
             a disease or condition that contraindicates the use of an investigational drug or that
             may affect the interpretation of the results or render the patient at high risk from
             treatment complications

          -  Known hypersensitivity to recombinant human antibodies

        Exclusion Criterion Unique to Arm B:

          -  Known significant hypersensitivity to paclitaxel or other drugs using the vehicle
             cremophor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer Brachmann, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2009</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumor</keyword>
  <keyword>Locally Advanced Solid Tumor</keyword>
  <keyword>Avastin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

